Betul Oran1, Daniel J Weisdorf. 1. University of Minnesota Hematology, Oncology and Transplantation, Minneapolis, Minnesota, USA. boran@mdanderson.org
Abstract
BACKGROUND: Acute myeloid leukemia is the second most common leukemia among United States adults with a median age of 69 years. We investigated recent clinical practices related to treatments and disease outcomes in older patients with acute myeloid leukemia in the United States. DESIGN AND METHODS: In this retrospective cohort study, we used Surveillance, Epidemiology, and End Results program data from 2000 through 2007 linked to Medicare enrollment and utilization data in the United States. RESULTS: Among 5,480 patients with acute myeloid leukemia (median age 78 years, range 65-93), 38.6% received leukemia therapy within three months of diagnosis (treated group). Practice changed with 16.3% of treated patients receiving hypomethylating agents after 2004 when those agents became available. Median survival was two months in the untreated group versus six months in the treated group (P<0.01) with the biggest improvements seen in those aged 65-69 years (10 months vs. 4 months; P<0.01) and 70-74 years (8 months vs. 3 months; P<0.01). In 46 patients receiving allogeneic hematopoietic cell transplantation (0.8%), the median survival from diagnosis was 22 months. CONCLUSIONS: Therapy for leukemia improves overall survival in older acute myeloid leukemia patients. Based on their comorbidities, most patients up to 80 years of age should be considered for treatment. New therapies including hypomethylating agents and allogeneic hematopoietic cell transplantation are promising and must be compared with other chemotherapy regimens.
BACKGROUND:Acute myeloid leukemia is the second most common leukemia among United States adults with a median age of 69 years. We investigated recent clinical practices related to treatments and disease outcomes in older patients with acute myeloid leukemia in the United States. DESIGN AND METHODS: In this retrospective cohort study, we used Surveillance, Epidemiology, and End Results program data from 2000 through 2007 linked to Medicare enrollment and utilization data in the United States. RESULTS: Among 5,480 patients with acute myeloid leukemia (median age 78 years, range 65-93), 38.6% received leukemia therapy within three months of diagnosis (treated group). Practice changed with 16.3% of treated patients receiving hypomethylating agents after 2004 when those agents became available. Median survival was two months in the untreated group versus six months in the treated group (P<0.01) with the biggest improvements seen in those aged 65-69 years (10 months vs. 4 months; P<0.01) and 70-74 years (8 months vs. 3 months; P<0.01). In 46 patients receiving allogeneic hematopoietic cell transplantation (0.8%), the median survival from diagnosis was 22 months. CONCLUSIONS: Therapy for leukemia improves overall survival in older acute myeloid leukemiapatients. Based on their comorbidities, most patients up to 80 years of age should be considered for treatment. New therapies including hypomethylating agents and allogeneic hematopoietic cell transplantation are promising and must be compared with other chemotherapy regimens.
Authors: Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544
Authors: Hendrik J M de Jonge; Eveline S J M de Bont; Peter J M Valk; Jan Jacob Schuringa; Marcel Kies; Carolien M Woolthuis; Ruud Delwel; Nic J G M Veeger; Edo Vellenga; Bob Löwenberg; Gerwin Huls Journal: Blood Date: 2009-08-10 Impact factor: 22.113
Authors: Sherif S Farag; Kati Maharry; Mei-Jie Zhang; Waleska S Pérez; Stephen L George; Krzysztof Mrózek; John DiPersio; Donald W Bunjes; Guido Marcucci; Maria R Baer; Mitchell Cairo; Edward Copelan; Corey S Cutler; Luis Isola; Hillard M Lazarus; Mark R Litzow; David I Marks; Olle Ringdén; David A Rizzieri; Robert Soiffer; Richard A Larson; Martin S Tallman; Clara D Bloomfield; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2011-06-21 Impact factor: 5.742
Authors: Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund Journal: Blood Date: 2008-11-13 Impact factor: 22.113
Authors: Jianping Mao; Wenliang Gao; Lianguo Xue; Lidong Zhao; Lei Miao; Tao Jia; Yuanxin Zhu; Ying Wang; Lijuan Meng; Juan Wang Journal: Am J Blood Res Date: 2020-12-15
Authors: Irina A Tikhonova; Martin W Hoyle; Tristan M Snowsill; Chris Cooper; Joanna L Varley-Campbell; Claudius E Rudin; Ruben E Mujica Mota Journal: Pharmacoeconomics Date: 2017-03 Impact factor: 4.981
Authors: Heidi D Klepin; Janet A Tooze; Timothy S Pardee; Leslie R Ellis; Dmitriy Berenzon; Shannon L Mihalko; Suzanne C Danhauer; Arati V Rao; Tanya M Wildes; Jeff D Williamson; Bayard L Powell; Stephen B Kritchevsky Journal: J Am Geriatr Soc Date: 2016-09-14 Impact factor: 5.562
Authors: L S G Østgård; J M Nørgaard; H Sengeløv; M Severinsen; L S Friis; C W Marcher; I H Dufva; M Nørgaard Journal: Leukemia Date: 2014-08-05 Impact factor: 11.528